Click here for text menu (or enable Javascript for regular menu).
Faculty Publications Home

Publications for Michael Clearfield

  • Clearfield, M. B. (2011, April). Cardiovascular benefits of aggressive cholesterol-lowering therapy. Journal of the American Osteopathic Association, 111(4 Suppl. 3), i-eS2.

  • Clearfield, M. B. (2011). Combination lipid therapy in type 2 diabetes. Current Atherosclerosis Reports, 13(1), 1-3. doi: 10.1007/s11883-010-0139-y

  • Clearfield, M. B. (2011). Statins in combination: From ARBITER-6 HALTS to ACCORD. What works? Current Atherosclerosis Reports, 13(1), 4-8. doi: 10.1007/s11883-010-0142-3

  • Cholesterol Treatment Trialists' Collaboration. (2010). Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials. The Lancet, 376(9753), 1670-1681. doi: 10.1016/S0140-6736(10)61350-5 This material can be found here.

  • Clearfield, M. B. (2010). Altering the pathophysiology of atherosclerosis: The multidimensional role of statins. Journal of the American Osteopathic Association, 110(4 Suppl. 4), 2-6. This material can be found here.

  • Clearfield, M. B. (2010). Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention. Current Atherosclerosis Reports, 12(1), 8-10. doi: 10.1007/s11883-009-0083-x This material can be found here.

  • Clearfield, M. B. (2010). New evidence extending the benefit of treating LDL-C beyond the current guidelines. Current Atherosclerosis Reports, 12(1), 1-4. doi: 10.1007/s11883-009-0081-z This material can be found here.

  • Clearfield, M. B. (2010). Rosuvastatin and clinical outcomes in individuals who are not deemed appropriate for baseline statin therapy. Current Atherosclerosis Reports, 12(1), 5-7. doi: 10.1007/s11883-009-0082-y This material can be found here.

  • Hiserote, P., & Clearfield, M. B. (2010). Treating risk components of the metabolic syndrome. Journal of the American Osteopathic Association, 110 (3, Suppl. 3), 6-13. This material can be found here.

  • Satter, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J. M., . . . Clearfield, M. B. (2010). Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials. The Lancet, 375(9716), 735-742. doi: 10.1016/S0140-6736(09)61965-6 This material can be found here.

  • Bray, G. A., Clearfield, M. B., Fintel, D. J., & Nelinson, D. S. (2009). Overweight and obesity: The pathogenesis of cardiometabolic risk. Clinical Cornerstone, 9(4), 30-42. doi: 10.1016/S1098-3597(09)80003-3 This material can be found here.

  • Cui, Y., Watson, D. J., Girman, C. J., Shapiro, D. R., Gotto, A. M., Hiserote, P., & Clearfield, M. B. (2009). Effects of increasing high-density lipoprotein cholesterol and decreasing low-density lipoprotein cholesterol on the incidence of first acute coronary events (from the Air Force/Texas Coronary Atherosclerosis Prevention Study). American Journal of Cardiology, 104(6), 829-834. This material can be found here.

  • Licciardone, J. C., Clearfield, M. B., & Guillory, V. J. (2009). Clinical practice characteristics of osteopathic and allopathic primary care physicians at academic health centers: Results from the National Ambulatory Medical Care Survey. Academic Medicine, 84(6), 744-750. doi: 10.1097/ACM.0b013e3181a424fc This material can be found here.

  • Shah, B., Kemp, R., & Clearfield, M. B. (2009) Using statins to treat healthy patients – are we there yet? Expert Review of Pharmacoeconomics and Outcomes Research, 9(2), 103-105. doi: 10.1586/erp.09.5 This material can be found here.